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Objectives We aimed to assess the predictive value of the SYNTAX score (SXscore) for major adverse cardiac events in the
all-comers population of the LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial.
Background The SXscore has been shown to be an effective predictor of clinical outcomes in patients with multivessel dis-
ease undergoing percutaneous coronary intervention.
Methods The SXscore was prospectively collected in 1,397 of the 1,707 patients enrolled in the LEADERS trial (patients
after surgical revascularization were excluded). Post hoc analysis was performed by stratifying clinical outcomes
at 1-year follow-up, according to 1 of 3 SXscore tertiles.
Results The 1,397 patients were divided into tertiles based on the SXscore in the following fashion: SXscore 8 (SXlow)
(n  464), SXscore 8 and 16 (SXmid) (n  472), and SXscore 16 (SXhigh) (n  461). At 1-year follow-up,
there was a significantly lower number of patients with major cardiac event–free survival in the highest tertile of
SXscore (SXlow  92.2%, SXmid  91.1%, and SXhigh  84.6%; p  0.001). Death occurred in 1.5% of SXlow
patients, 2.1% of SXmid patients, and 5.6% of SXhigh patients (hazard ratio [HR]: 1.97, 95% confidence interval
[CI]: 1.29 to 3.01; p  0.002). The myocardial infarction rate tended to be higher in the SXhigh group. Target
vessel revascularization was 11.3% in the SXhigh group compared with 6.3% and 7.8% in the SXlow and SXmid
groups, respectively (HR: 1.38, 95% CI: 1.1 to 1.75; p  0.006). Composite of cardiac death, myocardial infarc-
tion, and clinically indicated target vessel revascularization was 7.8%, 8.9%, and 15.4% in the SXlow, SXmid,
and SXhigh groups, respectively (HR: 1.47, 95% CI: 1.19 to 1.81; p  0.001).
Conclusions The SXscore, when applied to an all-comers patient population treated with drug-eluting stents, may allow pro-
spective risk stratification of patients undergoing percutaneous coronary intervention. (LEADERS Trial Limus
Eluted From A Durable Versus ERodable Stent Coating; NCT00389220). (J Am Coll Cardiol 2010;56:272–7)
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July 20, 2010:272–7 SYNTAX Score in an All-Comers Patient Populationhe SYNTAX score (SXscore) is a comprehensive angio-
raphic scoring system that is derived entirely from the
oronary anatomy and lesion characteristics (1–3). It was
nitially designed to quantify lesion complexity; however, it
s also able to predict major adverse cardiac events (MACE)
fter percutaneous revascularization in patients with mul-
ivessel coronary artery disease (4–6) and/or left main
isease (7). More recent data indicate its ability to predict
eriprocedural myocardial infarction (MI) in patients
ndergoing elective percutaneous coronary intervention
8). In this substudy of the LEADERS (Limus Eluted
rom A Durable versus ERodable Stent coating) trial, in
hich the SXscore was collected prospectively in 1,397
ll-comer patients, we assessed its prognostic value for
ACE at 1-year follow-up.
ethods
tudy population. LEADERS was a multicenter Euro-
ean noninferiority trial comparing the safety and efficacy of
he BioMatrix Flex biolimus-eluting stent with a biodegrad-
ble polymer (Biosensors, Morges, Switzerland) with the
ypher Select sirolimus-eluting stent with a durable poly-
er (Cordis, Bridgewater, New Jersey) in 1,707 all-comer
atients. Detailed study protocol can be found in the main
eport (9). The study complied with the Declaration of
elsinki and was approved by all institutional ethics com-
ittees. All patients provided written informed consent for
articipation in the trial.
Xscore and angiographic analysis. From the baseline
iagnostic angiogram, each coronary lesion producing
50% diameter stenosis in vessels 1.5 mm was scored
eparately and added together to provide the overall
Xscore, which was calculated prospectively using the
Xscore algorithm (described in full elsewhere) (1–3). All
ngiographic variables pertinent to SXscore calculation were
omputed by blinded core laboratory analysts (Cardialysis
.V., Rotterdam, the Netherlands). The SXscore is not
urrently validated in patients with acute MI or previous
ercutaneous coronary intervention and coronary artery
ypass graft. Core laboratory analysts were blinded to all
linical data, and therefore patients with occluded infarct–
elated arteries were scored as occlusions of unknown
uration in a similar manner to any chronically occluded
rtery. Those patients with in-stent restenosis lesions were
cored in the same manner as if the lesion was a de novo
esion.
tudy end points. Definitions of all end points are pro-
ided elsewhere (9). The primary end point of this substudy
as MACE, defined as the composite of cardiac death, MI,
nd clinically indicated target vessel revascularization
TVR) within 9 months. Secondary end points were any
arget lesion revascularization (both clinically and nonclini-
ally indicated), any TVR, cardiac death, death from any
ause, MI, stent thrombosis (defined according to the Ccademic Research Council
10]), device success, and lesion
uccess.
The pre-specified principal
utcome of the angiographic
ubstudy was the in-stent per-
entage of diameter stenosis.
econdary angiographic out-
omes were the in-segment per-
entage of diameter stenosis,
inimal lumen diameter, late lu-
en loss, and binary restenosis.
tatistical analysis. A stratified
ost hoc analysis of clinical and
ngiographic outcomes was per-
ormed according to the tertiles
f the SXscore (4,5). Dedicated
oftware and visual coronary angiography served to deter-
ine the SXscore (1,2). All randomized patients without
revious surgical revascularization (1,397 of 1,707) were
ncluded in the analysis. Angiographic outcomes were ana-
yzed using SAS version 8 (SAS Institute, Cary, North
arolina) Proc Mixed for continuous and Proc Genmod
or binominal outcomes, taking into account the within-
atient correlation structure of these data. The Cox
roportional hazards model was used to compare clinical
utcomes among the groups. All analyses were performed
sing SAS version 8.02 by a dedicated statistician. All p
alues and confidence intervals (CIs) were 2-sided. Mul-
ivariate model included SXscore, diabetes, beta-blocker
se, stent type, and the presence of acute coronary
yndrome as covariates. Testing for (linear) trend was
one by using generalized linear models with SYNTAX
lass as a covariable for continuous variables and the
ochran-Armitage test for trend in categorical data.
esults
Xscore and baseline characteristics. The SXscore was
ollected prospectively in 1,397 of the 1,707 patients
81.8%) enrolled in the LEADERS trial. The score ranged
rom 0 to 49, with a mean SD of 13.5 8.7 and a median
f 12 (interquartile range 7 to 19). In this post hoc analysis,
he SXscore tertiles were defined as SXlow (SXscore 8)
n  464), SXmid (SXscore 8 and 16) (n  472), and
Xhigh (SXscore 16) (n  461). Baseline clinical and
ngiographic characteristics of the patients are listed in
ables 1 and 2.
-year outcomes. The SXscore significantly predicted the
ate of MACE at 360 days (Table 3, Figs. 1 to 4). There was
lower number of patients with MACE-free survival in the
ighest tertile of the SXscore (SXlow 92.2%, SXmid 91.1%,
nd SXhigh  84.6%; p  0.001). Death occurred in 1.5%
f patients with SXlow, 2.1% of patients with SXmid, and
.6% of patients with SXhigh (hazard ratio [HR]: 1.97, 95%
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
SXhigh  SYNTAX
score >16
SXlow  SYNTAX score <8
SXmid  SYNTAX score >8
and <16
SXscore  SYNTAX score
TVR  target vessel
revascularizationI: 1.29 to 3.01; p  0.002). The rate of MI tended to be
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SYNTAX Score in an All-Comers Patient Population July 20, 2010:272–7igher in patients with SXhigh (MI HR: 1.2, 95% CI: 0.9
o 1.61; p  0.22). TVR was 11.3% in the SXhigh group
ompared with 6.3% and 7.8% in the SXlow and SXmid
roups, respectively (HR: 1.38, 95% CI: 1.1 to 1.75; p 
.006). Composite of cardiac death, MI, and clinically
ndicated TVR was 7.8%, 8.9%, and 15.4% in the SXlow,
Xmid, and SXhigh groups, respectively (HR: 1.47, 95%
I: 1.19 to 1.81; p  0.001).
ultivariate model. In a multivariate model, SXscore
emained a significant predictor of MACE and mortality.
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Baseline Clinical Variables
SXlow
(n  464)
Age 65 yrs 210 (45.3
Male 346 (74.6
Diabetes 93 (20.0
Current smoking 134 (28.9
Hypertension 353 (76.1
Hypercholesterolemia 314 (67.7
Family history of coronary artery disease 201 (43.3
Renal insufficiency 17 (3.7)
Previous MI 132 (28.5
Previous PCI 179 (38.6
PVD 26 (5.6)
Previous stroke 13 (2.8)
Clinical presentation
Stable 146 (31.5
Unstable 127 (27.4
STEMI 46 (9.9)
Non-STEMI 90 (19.4
Silent ischemia 55 (11.9
Values shown are n (%).
MI  myocardial infarction; PCI  percutaneous coronary interve
myocardial infarction; SXhigh  SYNTAX score 16; SXlow  SYNTAX
aseline Angiographic CharacteristicsTable 2 Baseline Angiographic Characteristics
Angiographic Variables
No. of diseased lesions per patient (based on SYNTAX application) 1
No. of treated lesions per patient (as defined by the core laboratory)
Ratio of diseased to treated lesions
Coronary artery treated
LAD
LCX
RCA
2-vessel disease
3-vessel disease
Stent type
Biolimus-eluting
Sirolimus-eluting
No. of implanted stents 1
Total stent length/patient, mm 2
Chronic total occlusion
Moderate to severe calcification
Bifurcation lesion
Use of glycoprotein IIb/IIIa inhibitoralues are mean  SD or n (%).
LAD  left anterior descending artery; LCX  left circumflex artery; N/A  not applicable; RCA  rightatients in the SXhigh group had a 50% greater chance of
he composite of cardiac death, MI, and clinically indicated
VR than patients in the SXmid group (p  0.001), which
as comparable to the 51% higher composite event rate
mong diabetic patients (p  0.022). Use of the biolimus-
luting stent tended to reduce the composite event rate by
6% (p  0.07).
tent thrombosis rates. The rates of definite stent throm-
osis were 0.9%, 2.1%, and 3.5% in the SXlow, SXmid, and
Xhigh groups, respectively.
SXmid
(n  472)
SXhigh
(n  461)
p Value on Trend
(2-Sided)
224 (47.5) 239 (51.8) 0.048
344 (72.9) 340 (73.8) 0.79
117 (24.8) 111 (24.1) 0.15
121 (25.6) 126 (27.3) 0.61
353 (74.8) 324 (70.3) 0.048
314 (66.5) 285 (61.8) 0.06
188 (39.8) 168 (36.4) 0.034
21 (4.5%) 28 (6.1) 0.09
145 (30.7) 137 (29.7) 0.69
165 (35.0) 147 (31.9) 0.036
36 (7.6) 31 (6.7) 0.51
19 (4.0) 16 (3.5) 0.59
154 (32.6) 108 (23.4) 0.008
89 (18.9) 88 (19.1) 0.002
90 (19.1) 128 (27.8) 0.0001
90 (19.1) 97 (21.0) 0.54
49 (10.4) 40 (8.7) 0.12
VD  peripheral vascular disease; STEMI  ST-segment elevation
8; SXmid  SYNTAX score 8 and 16.
w SXmid SXhigh p Value
0.66 2.37 1.00 3.45 1.44 0.001
0.46 1.47 0.7 1.69 0.86 0.001
2 1.61 2.04 N/A
4.9) 242 (51.3) 296 (64.2) 0.001
0.2) 144 (30.5) 164 (35.6) 0.079
6.6) 209 (44.3) 174 (37.7) 0.007
0.6) 102 (21.6) 138 (29.9) 0.001
.7) 13 (2.8) 23 (5.0) 0.001
9.3) 235 (49.8) 239 (51.8) 0.45
0.7) 237 (50.2) 222 (48.2) 0.45
0.8 1.90 1.12 2.33 1.39 0.001
16.5 34.2 21.7 42.9 26.2 0.001
.3) 10 (2.1) 19 (4.1) 0.006
.1) 96 (20.3) 184 (39.9) 0.001
2.3) 161 (34.1) 184 (39.9) 0.001
7.2) 113 (23.9) 154 (33.4) 0.001)
)
)
)
)
)
)
)
)
)
)
)
)SXlo
.47
1.2
1.2
162 (3
140 (3
216 (4
49 (1
3 (0
229 (4
235 (5
.47
5.9
6 (1
23 (5
57 (1
80 (1coronary artery; other abbreviations as in Table 1.
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July 20, 2010:272–7 SYNTAX Score in an All-Comers Patient Populationiscussion
omplexity of disease and lesion characteristics are well
ecognized predictors of periprocedural complications (8)
nd long-term mortality (11–13). The SXscore was devel-
ped to comprehensively assess lesion characteristics and is
ased on the combination of classifications from the Amer-
can Heart Association/American College of Cardiology,
odified BARI classification, chronic total occlusion and
ifurcation scores, and Leaman classification (1). It has
reviously been applied in both the SYNTAX trial and
he ARTS II (Arterial Revascularization Therapies Study
I), both of which demonstrated the good predictive value
f the SXscore in patients with multivessel disease, with
he highest tertile patients having significantly more
ACE during short-term (4,5) and long-term (6)
ollow-up.
linical Outcomes at 360 Days After Index PCI Based on Tertiles oTable 3 Clinical Outcomes at 360 Days After Index PCI Based
Type of Event Risk Factors Used
SXlow
(%)
Death SYNTAX class, DM, STEMI 1.5
Stent thrombosis SYNTAX class, DM, STEMI 1.1
MI SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
4.3
All TVR SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
6.3
All TLR SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
4.7
Composite of cardiac
death, MI, clinically
indicated TVR
SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
7.8
ES biolimus-eluting stent(s); DM diabetes mellitus; HR hazard ratio; PCI percutaneous c
essel revascularization; other abbreviations as in Table 1.
Figure 1 Kaplan-Meier Curves for MACE at 360 Days According
Patients in the highest tertile of the SYNTAX score have an increased major adverThis study is the first to report the utility of the SXscore
s a predictor of MACE, including cardiac death, in an
ll-comers population including patients with acute coro-
ary syndromes. Overall, this patient population had much
ower SXscores than the SYNTAX trial population; how-
ver, despite this, the SXscore still appears to have good
iscriminatory power for risk assessment.
tudy limitations. The limitation of the SXscore is that it
oes not incorporate clinical patient characteristics. Patients
ho underwent previous coronary artery bypass graft sur-
ery have not been included because the SXscore algorithm
s only currently available for patients with de novo disease.
odifications to the SXscore for risk stratification in
atients after coronary artery bypass graft surgery are cur-
ently being developed. The SXscore of patients who
resented with acute MI or had previous percutaneous
coreertiles of SXscore
mid
%)
SXhigh
(%)
p Value
SYNTAX
HR,
SYNTAX
Lower Limit HR,
SYNTAX
Upper Limit HR,
SXscore
.1 5.6 0.002 1.97 1.29 3.01
6.1 0.001 2.13 1.4 3.24
.9 5.9 0.22 1.2 0.9 1.61
.8 11.3 0.006 1.38 1.1 1.75
.1 8.7 0.019 1.37 1.05 1.79
.9 15.4 0.001 1.47 1.19 1.81
intervention; SES sirolimus-eluting stent(s); TLR target lesion revascularization; TVR target
he SYNTAX Tertiles
diac events (MACE) event rate (p  0.0002).f SXson T
SX
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SYNTAX Score in an All-Comers Patient Population July 20, 2010:272–7oronary intervention were included in this analysis, despite
o previous validation in these patients. Scoring of the
nfarct-related vessel as a chronic total occlusion may
onfound the results and have complex effects on the
Xscore. There is the danger of overestimating the SXscore
f all ST-segment elevation MIs with an occluded infarct–
elated vessel are taken as chronic total occlusions, particu-
arly because the lesion is likely to be easier to treat due to
he soft nature of plaque as opposed to an occlusion, which
as calcified organized old thrombus and plaque (chronic
cclusion). Alternatively, there is the danger of underesti-
ating the SXscore because the underlying lesion complex-
Figure 2 Kaplan-Meier Curves for Cardiac Death at 360 Days A
Patients in the highest tertile of the SYNTAX score have a higher cardiac death rat
Figure 3 Kaplan-Meier Curves for All Myocardial Infarctions at
There is no difference in the rate of overall myocardial infarctions across the tertilty will not be accounted for because the vessel beyond the
cclusion is not seen due to the occlusion. This is the subject
f an ongoing study. This study may have limitations
nherent to subgroup analysis (chance findings and under-
owering) (14–16).
onclusions
his study demonstrates that the prognostic value of the
Xscore is valid for all patients with de novo coronary
rtery disease undergoing percutaneous revascularization.
ding to the SYNTAX Score Tertiles
0.0001).
Days According to the SYNTAX Score Tertiles
YNTAX score (p  0.548 [NS]).ccor
e (p 360
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